Patent · US Active

ULK1 inhibitors and methods using same

US10774092B2 · kind B2 · utility

0Cited by
6References
20Claims
0Family size

Assignees

Inventors

Key dates

Filing dateApr 19, 2019
Grant dateSep 15, 2020
Priority date—
Expiry dateApr 19, 2039

Classification

  • Technology area (CPC G)Physics
  • CPC primaryG01N2800/52
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

In certain aspects, the invention provides a method for treating a disease or condition in a subject, the method comprising co-administering to a subject in need thereof a therapeutically effective amount of at least one ULK1-inhibiting pyrimidine, and a therapeutically effective amount of an mTOR inhibitor.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.